Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics develops novel product candidates for immuno-inflammatory diseases as a clinical-stage biopharmaceutical company. News about ACRS centers on clinical and corporate updates for ATI-052, an investigational anti-TSLP/IL-4Rα bispecific antibody; ATI-2138, an oral ITK/JAK3 inhibitor; and bosakitug (ATI-045), an anti-TSLP antibody program. Recurring updates include trial results and medical-meeting presentations in dermatology and inflammatory disease, development work in atopic dermatitis, lichen planus and asthma, financial results, R&D spending, royalty revenue from license agreements and healthcare conference presentations.
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.
The event is scheduled for June 4, 2026 at 2:00 PM ET, with a live and archived webcast available on Aclaris’ website for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) will present at the 2026 Bank of America Healthcare Conference in Las Vegas on May 14, 2026 at 9:35 AM PT. Dr. Hugh Davis, President and COO, will deliver the corporate presentation. A live and archived webcast will be available on the company website for at least 30 days.
Aclaris (NASDAQ: ACRS) reported Q1 2026 results and clinical updates on May 7, 2026. Key clinical highlights include positive Phase 1a SAD/MAD results for bispecific antibody ATI-052 with an estimated half-life ~45 days and sustained PD through week 20 in the 480 mg cohort. The company completed bosakitug Phase 2 enrollment (109 patients) and plans Phase 2b for ATI-052 and an IND for ATI-9494 in H2 2026. Financially, cash and investments totaled $190.8M at March 31, 2026; the company expects runway through end of 2028. Q1 net loss was $19.8M.
Aclaris Therapeutics (NASDAQ: ACRS) reported positive full top-line Phase 1a SAD/MAD results for ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing an estimated half-life of ~45 days and sustained PD activity supporting up to three-month dosing.
The company also selected lichen planus as the lead indication for oral ITK/JAK3 inhibitor ATI-2138 and plans Phase 2b programs in 2H 2026; Phase 1b ATI-052 trials in asthma and atopic dermatitis have top-line results expected in 2H 2026.
Aclaris Therapeutics (NASDAQ: ACRS) will release full Phase 1a results for its anti-TSLP/IL-4R bispecific antibody ATI-052 and announce lead indication selection for its ITK/JAK3 inhibitor ATI-2138 before markets open on April 28, 2026.
The company will host a webcast and conference call with slides on April 28, 2026 at 8:30 AM EST; the live and archived webcast will be available on the company Events page and archived for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026 at 12:00 PM EDT.
CEO Dr. Neal Walker and senior leaders will join a fireside chat; a live webcast and archived replay will be available on the company website for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) presented Phase 2a ePoster results for oral ATI-2138 at the 2026 AAD meeting showing rapid, sustained improvements in atopic dermatitis measures at week 12.
Key week-12 outcomes for 10 mg BID included EASI -77%, BSA -70%, PP-NRS -50%, POEM -55%, and DLQI -65%, plus near-complete ITK occupancy and multi-pathway modulation.
Aclaris Therapeutics (NASDAQ: ACRS) announced an ePoster presenting previously unreported results from its open-label Phase 2a trial of ATI-2138 for moderate-to-severe atopic dermatitis at the 2026 AAD Annual Meeting in Denver, CO on March 20, 2026.
ATI-2138 is described as an investigational oral covalent inhibitor targeting ITK and JAK3. The poster lists Aclaris and Mount Sinai authors and will be available electronically during the meeting.
Aclaris Therapeutics (NASDAQ: ACRS) completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis, enrolling 109 patients. Top-line results are expected in the fourth quarter of 2026.
The trial's primary endpoint is percent change from baseline in EASI at week 24; secondary endpoints include EASI-50/75/90, IGA, BSA, and PP-NRS. Safety, PD biomarkers, and PK will be assessed. The company cites a 23-day natural half-life and potential dosing convenience as product attributes.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026 at 1:40 PM EDT. CEO Dr. Neal Walker and senior leaders will join a fireside chat. A live and archived webcast will be available on the company Events page for at least 30 days.